Estimating the prevalence of illicit opioid use in New York City using multiple data sources

BMC Public Health

Daliah Heller³  Shana Wright⁵  Sharmila Shah¹  Denise Paone¹  Marc N Gourevitch⁴  Jennifer McNeely² 

[1] Bureau of Alcohol and Drug Use Prevention, Care and Treatment, New York City Department of Health and Mental Hygiene, Long Island City, NY, 11101, USA;Division of General Internal Medicine, Department of Medicine, NYU School of Medicine, New York, NY, 10016, USA;Center for Health Media and Policy, Hunter-Bellevue School of Nursing, City University of New York, New York, NY, 10010, USA;Department of Population Health, NYU School of Medicine, New York, NY, 10016, USA;Department of Psychiatry, NYU School of Medicine, New York, NY, 10016, USA

关键词: Epidemiology;    Heroin;    Opioids;    Prevalence;    Substance abuse;    Substance use;   

Others  :  1163532
DOI  :  10.1186/1471-2458-12-443

 received in 2012-03-14, accepted in 2012-06-18,  发布年份 2012

【 授权许可】

   
2012 McNeely et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Frank B: An overview of heroin trends in New York City: Past, present and future. Mt Sinai J Med 2000, 67(5–6):340-346.
• [2]Lange WR, White N, Robinson N: Medical complications of substance abuse. Postgrad Med 1992, 92:205-214.
• [3]Gossop M, Stewart D, Treacy S, Marsden J: A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2001, 97:39-47.
• [4]Hulse GK, English DR, Milne E, Holman CD: The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999, 94:221-229.
• [5]Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K: Opiates, cocaine and alcohol combinations in drug overdose deaths in New York City, 1990–98. Addiction 2003, 98(6):739-747.
• [6]Paone D, Heller D, Olson C, Kerker B: Illicit drug use in new york city. NYC Vital Signs 2010, 9(1):1-4. http://www.nyc.gov/html/doh/downloads/pdf/survey/survey-2009drugod.pdf webcite
• [7]Center for Substance Abuse Research (CESAR): Unintentional drug overdose deaths continue to increase; now second leading cause of unintentional deaths. CESAR FAX 2011, 20(19):1.
• [8]Centers for Disease Control and Prevention: Unintentional poisoning deaths – United States, 1999–2004. MMWR Morbid Mortal Wkly Rep 2007, 56(5):93-96.
• [9]Centers for Disease Control and Prevention National Center for Injury Prevention and Control: Unintentional drug poisoning in the United States. CDC, Atlanta, GA; 2010. http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf webcite
• [10]Substance Abuse and Mental Health Services Administration Office of Applied Studies: Trends in Emergency Department visits involving nonmedical use of narcotic pain relievers. The DAWN Report, Rockville, MD; 2010. http://www.oas.samhsa.gov/2k10/DAWN016/OpioidED.cfm webcite
• [11]Substance Abuse and Mental Health Services Administration Office of Applied Studies: The NSDUH Report: Trends in nonmedical use of prescription pain relievers: 2002 to 2007. SAMHSA, Rockville, MD; 2009. http://www.oas.samhsa.gov/2k9/painRelievers/nonmedicalTrends.pdf webcite
• [12]McCabe SE, Cranford JA, West BT: Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav 2008, 33(10):1297-1305.
• [13]Johnson BD, Rosenblum A, Kleber H: A White Paper: a new opportunity to expand treatment for heroin users in New York City: Public policy challenges for bringing buprenorphine into drug treatment programs and general medical practice. New York City Department of Health and Mental Hygiene, New York, NY; 2003. http://www.nyc.gov/html/doh/downloads/pdf/basas/whitepaper.pdf webcite
• [14]New York City Department of Health and Mental Hygiene: City of New York. Local Governmental Plan Alcohol and Drug Use Services. NYC DOHMH, New York, NY; 2009. http://www.nyc.gov/html/doh/downloads/pdf/basas/basas-localgovtplan-2009.pdf webcite
• [15]Office of National Drug Control Policy: National Drug Control Strategy. ONDCP, Washington, DC; 2010. http://www.whitehousedrugpolicy.gov/publications/policy/ndcs10/ndcs2010.pdf webcite
• [16]Cooper HLF, Brady JE, Friedman SR, Tempalski B, Gostnell K, Fom PL: Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992–2002): Estimation methods and prevalence trends. J Urban Health 2008, 85(6):826-856.
• [17]Wright D, Gfroerer J, Epstein J: The use of external data sources and ratio estimation to improve estimates of hardcore drug use from the NHSDA. NIDA Res Monogr 1997, 167:477-497.
• [18]Compton WM, Dawson D, Duffy SQ, Grant BF: The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States. Am J Psychiatry 2010, 167(4):473-75.
• [19]Substance Abuse and Mental Health Services Administration Office of Applied Studies: Development of computer-assisted interviewing procedures for the National Survey on Drug Abuse. SAMHSA, Rockville, MD; 2008. http://www.oas.samhsa.gov/NHSDA/CompAssistInterview/toc.htm webcite
• [20]ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders: ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders. In ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders. Secondth edition. Edited by Mee-Lee D, Shulman GD, Fishman M, Gastfriend DR, Griffith H, Chevy Chase MD. American Society of Addiction Medicine, Inc, ; 2001.
• [21]Diagnostic and statistical manual of mental disorders: 4th. American Psychiatric Association, Washington, DC; 2000.
• [22]New York State Department of Health: Statewide Planning and Research Cooperative System (SPARCS). NYS DOH, Albany, NY; . http://www.health.state.ny.us/statistics/sparcs/operations/overview.htm webcite
• [23]Substance Abuse and Mental Health Services Administration Office of Applied Studies: Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. SAMHSA, Rockville, MD; 2011. http://www.oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm webcite
• [24]Substance Abuse and Mental Health Services Administration Office of Applied Studies: Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, Appendix B. SAMHSA, Rockville, MD; 2011. http://www.oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm#AppB webcite
• [25]City of New York Department of Correction: DOC Statistics. DOC, New York, NY; 2012. http://www.nyc.gov/html/doc/html/stats/doc_stats.shtml webcite
• [26]Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network (DAWN): Methodology Report. SAMHSA, Rockville, MD; 2009. http://www.samhsa.gov/data/2k11/DAWN/2009Methods/DAWN2k9_MethodologyReport.htm webcite
• [27]European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Methodological guidelines to estimate the prevalence of problem drug use on the local level. EMCDDA, Lisbon; 1999.
• [28]Rehm J, Room R, van den Brink W, Kraus L: Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharm 2005, 15(4):389-397.
• [29]National Quality Forum: National voluntary consensus standards for the treatment of substance use conditions: Evidence-based treatment practices. National Quality Forum, Washington, DC; 2007.
• [30]Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R: Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alc Depend 2005, 77:49-59.
• [31]Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW: Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. Drug Alc Depend 2009, 99(1–3):280-95.
• [32]Domingo-Salvany A, Hartnoll RL, Maguire A, Brugal MT, Albertin P, Cayla JA, Casabona J, Suelves JM: Analytical considerations in the use of capture-recapture to estimate prevalence: case studies of the estimation of opiate use in the metropolitan area of Barcelona, Spain. Am J Epidemiol 1998, 148(8):732-740.
• [33]Hickman M, Cox S, Harvey J, Howes S, Farrell M, Frischner M, Stimson G, Taylor C, Tilling K: Estimating the prevalence of problem drug use in inner London: a discussion of three capture-recapture studies. Addiction 1999, 94(11):1653-1662.
• [34]Hall WD, Ross JE, Lynskey MT, Law MG, Degenhardt LJ: How many dependent heroin users are there in Australia? Med J Aust 2000, 173(10):528-531.
• [35]Hickman M, Hope V, Platt L, Higgins V, Bellis M, Rhodes T, Taylor C, Tilling K: Estimating prevalence of injecting drug use: a comparison of multiplier and capture-recapture methods in cities in England and Russia. Drug Alcohol Rev 2006, 25(2):131-40.
• [36]Stein MD, Wilkinson J, Berglas N, O'Sullivan P: Prevalence and detection of illicit drug disorders among hospitalized patients. Am J Drug Alcohol Ab 1996, 22(3):463-471.
• [37]Bjornaas MA, Hovda KE, Mikalsen H, Andrew E, Rudberg N, Ekeberg O, Jacobsen D: Clinical vs. laboratory identification of drugs of abuse in patients admitted for acute poisoning. Clin Toxicol 2006, 44(2):127-134.
• [38]Olfson M, Tobin J, Cassells A, Weissman M: Improving the detection of drug abuse, alcohol abuse, and depression in community health centers. J Health Care Poor U 2003, 14(3):386-402.
• [39]Saitz RS, Freedner N, Palfai TP, Horton NJ, Samet JH: The severity of unhealthy alcohol use in hospitalized medical patients: The spectrum is narrow. J Gen Int Med 2006, 21:381-85.
• [40]O'Malley K, Cook K, Price M, Wildes K, Hurdle J, Ashton C: Measuring diagnoses: ICD code accuracy. Health Serv Res 2005, 40(5):1620-1639.
• [41]Frayne S, Miller D, Sharkansky E, Jackson WV, Wang F, Halanych JH, Berlowitz DR, Kader B, Rosen CS, Keane TM: Using administrative data to identify mental illness: what approach is best? Am J Med Qual 2010, 25(1):42-50.
• [42]Young TW, Pollock DA: Misclassification of deaths caused by cocaine. An assessment by survey. Am J Foren Med Path 1993, 14(1):43-47.
• [43]Rappo P: Coding for mental health and behavioral problems: the arcane elevated to the ranks of the scientific. Pediatrics 2002, 110(1):167-168.
• [44]Perez-Stable EJ, Miranda J, Munoz RF, Ying YW: Depression in medical outpatients: Underrecognition and misdiagnosis. Arch Int Med 1990, 150(5):1083-88.
• [45]Kissin W, McLeod C, Sonnefeld J, Stanton A: Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006, 25(4):91-103.17088229.
• [46]Fiellin DA: The first three years of buprenorphine in the United States: Experience to date and future directions. J Addict Med 2007, 1(2):62-67.
• [47]West JC, Kosten TR, Wilk J, Svikis D, Triffleman E, Rae DS, Narrow WE, Duffy FF, Regier DA: Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict 2004, 13(supp 1):S8-16.
• [48]Saitz R, Alford DP, Bernstein J, Cheng DM, Samet J, Palfai T: Screening and brief intervention for unhealthy drug use in primary care settings: Randomized clinical trials are needed. J Addict Med 2010, 4(3):123-130.